G
Genetron Health
Specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment
About Genetron Health
Genetron Health is a precision oncology company focused on providing a full-cycle of cancer care solutions, primarily within the Chinese market. The company was co-founded in 2013 by Sizhen Wang, who serves as CEO, and Dr. Hai Yan, the Chief Scientific Officer. Wang is a serial entrepreneur with a background in financial services at Capital One and a previous venture, iTalkBB. Dr. Yan is a distinguished researcher in neuro-oncology, renowned for his work at Duke University and for identifying key genetic mutations in gliomas, which has significantly influenced tumor diagnosis and treatment.
The company's business model is structured around three main segments: diagnostics and monitoring, early screening, and biopharmaceutical development services. Revenue is primarily generated through two main channels: laboratory-developed testing (LDT) services provided via its central and joint hospital labs, and the sale of in-vitro diagnostic (IVD) products, such as medical devices and kits. The diagnostics and monitoring division represents the largest portion of revenue. Genetron Health serves a diverse client base including hospitals, physicians, pharmaceutical companies, and research institutions. It has established partnerships with over 500 hospitals and dozens of pharmaceutical firms. The company has also collaborated with global entities like AstraZeneca, Roche, and Siemens Healthineers to advance precision oncology.
Genetron Health's portfolio covers early screening, diagnosis, treatment recommendations, and continuous monitoring. A key technological innovation is the "Mutation Capsule," a platform for early cancer screening, which received FDA Breakthrough Device designation for its blood-based NGS test for early detection of hepatocellular carcinoma. Its products utilize next-generation sequencing (NGS) technology to analyze patient DNA for customized treatment plans. For biopharma partners, the company offers a suite of services including biomarker evaluation, clinical trial testing, and companion diagnostics development, leveraging its CAP and CLIA-certified laboratories. The company went public on the Nasdaq in June 2020, raising approximately $260 million in one of the largest IPOs for a Chinese healthcare company at the time. However, after facing market challenges, the company accepted a privatization offer led by CEO Sizhen Wang and was delisted from Nasdaq in March 2024.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 94
- Open positions
- 1
- Dealroom signal
- 71.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 4 companies, latest Oct 2023
- Capital deployed
- $12M
- Preferred round
- SERIES A
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Jun 2020 | $0 | — | Undisclosed | — |
| SERIES DOther financing | Nov 2019 | $71M | $284M | Alexandria Venture Investments · Vivo Capital · Highlight Capital | — |
Growth signals
Latest recorded traffic for Genetron Health is 310 monthly website visits, down 67% over the last three months. Genetron Health's team grew 3.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Arima GenomicsSan Diego, United StatesBiotechnology company commercializing a new standard in DNA sequencing
$88Mvaluation
Hangzhou ImmuQuad(艾沐蒽) Biotech, LLC.Chicago, United StatesImmune-driven medicine for diagnosing and treating diseases
→
Genetron Health in the Dongcheng District ecosystem
The Genetron Health office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Share Capital
Origene Technologies- ZEZhongyuan Union Cell & Gene Eng
New Horizon Capital
Series B and later3 investors entered at this stage
Alexandria Venture Investments
Vivo Capital
Highlight Capital
Other known investors2 additional known investors
Duke University
Technology Pioneers | World Economic Forum
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Genetron Health on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genetron Health’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








